FORM 3

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

APPROVAI	

OMB Number:	3235-0104					
Estimated average burden						
hours per response:	0.5					

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Banjak Marc		2. Date of Event Requiring Statement (Month/Day/Year) 08/14/2024	, , ,					
(Last)	(First)		Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date of Original Filed (Month/Day/Year)		
C/O IBIO, INC. 11750 SORRENTO VALLEY ROAD			X	Officer (give title below)  Chief Lega	10% Owner Other (specify below)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person		
(Street) SAN DIEGO	CA	92121			2		Form filed by More than One Reporting Person	
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	` ` '	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Nature of Indirect Beneficial Ownership (Instr. 5)	
Common Stock (RSU)	1,875(1)	D		

# Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	(D) or	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	02/21/2022	02/21/2032	Common Stock	800(2)	170.4	D	
Stock Option (Right to Buy)	08/29/2022	08/29/2032	Common Stock	600(2)	141.2	D	
Stock Option (Right to Buy)	08/23/2023	08/23/2033	Common Stock	3,000(2)	6.92	D	
Stock Option (Right to Buy)	04/25/2024	04/25/2034	Common Stock	29,000(2)	1.72	D	
Stock Option (Right to Buy)	05/09/2024	05/09/2034	Common Stock	55,000(3)	1.88	D	

## Explanation of Responses:

- 1. Consists of 1,875 shares of iBio, Inc. (the "Company") common stock, \$0.001 par value per share (the "Common Stock") represented by 1,875 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The 1,875 RSUs vested pro rata quarterly over 12 months and consists of 468 RSUs which fully vested on June 30, 2023, 469 RSUs which fully vested on September 30, 2023, 469 RSUs which fully vested on March 31, 2024.
- 2. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by the Company.
- 3. These options vest in equal amounts on a quarterly basis over a 3-year period commencing on the date of grant, provided that the reporting person remains employed by the Company

/s/ Marc Banjak 08/14/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.